Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac

Safety data following the COVID-19 booster mRNA vaccine in solid cancer patients are scarce. We prospectively evaluated adverse events after a booster dose of the BNT162b2 vaccine as compared to the mRNA-1273 vaccine in solid malignancy patients who had previously received two doses of ChAdOx1 or he...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Passakorn Wanchaijiraboon, Panot Sainamthip, Nattaya Teeyapun, Sutima Luangdilok, Yong Poovorawan, Nasamon Wanlapakorn, Suebpong Tanasanvimon, Virote Sriuranpong, Thiti Susiriwatananont, Nicha Zungsontiporn, Nussara Pakvisal
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	MDPI AG 2023-02-01
Serie:	Vaccines
Soggetti:	ChAdOx1 CoronaVac BNT162b2 mRNA-1273 booster COVID-19 vaccine safety
Accesso online:	https://www.mdpi.com/2076-393X/11/2/356
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!